These filings are necessary prior to the anticipated global roll-out of the company’s BioNanoChannel rapid bacteria/microorganism detection technology and also contribute to the protection of NanoLogix’s ongoing Hydrogen Bioreactor development.
Chris Novak, NanoLogix director of IP, said: “The strength and improved focus of the new foreign cases arose from significant improvements to the originally filed provisional patent applications. We at NanoLogix are very excited about the potential for enhancing the patent protection for these new technologies.”
Bret Barnhizer, NanoLogix president and CEO, said: “This is a step forward for the company in its plans for technological and business development and sets the stage for one of our corporate goals of pursuing licensing opportunities for use of our products internationally. These applications aid us by ensuring that NanoLogix strengthens their control over the intellectual property rights to the technology.”